| Symbol | KRRO |
|---|---|
| Name | KORRO BIO, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 60 FIRST STREET,2ND FLOOR,SUITE 250, CAMBRIDGE, Massachusetts, 02141, United States |
| Telephone | +1 617 - 468-1999 |
| Fax | — |
| — | |
| Website | https://www.korrobio.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001703647 |
| Description | Korro Bio, Inc. is a biopharmaceutical company. The Company discovers, develops, and commercializes genetic medicines based on editing ribonucleic acid (RNA), enabling treatment of both rare and highly prevalent diseases. The Company is generating a portfolio of differentiated programs that are designed to harness the bodys natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, it is expanding the reach of genetic medicines. Its Oligonucleotide Promoted Editing of RNA (OPERA) is a foundational platform for RNA editing, which is designed to edit RNA in vivo by delivering an oligonucleotide guide that can target specific RNA sequences. The Companys first development candidate, KRRO-110, is in development as a potential treatment for Alpha-1 Antitrypsin Deficiency (AATD), that has the potential to be disease-modifying and provide a differentiated therapeutic option. Additional info from NASDAQ: |
New Form SCHEDULE 13G/A - Korro Bio, Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001172661-26-003427 <b>Size:</b> 15 KB
Read moreLynx1 Capital Management LP 🟢 acquired 6.7K shares of Korro Bio, Inc. (KRRO) at $13.19 Transaction Date: Aug 06, 2026 | Filing ID: 003434
Read more📋 Atlas Venture Opportunity Fund II, L.P. (Shareholder) plans to sell 368 shares of Korro Bio, Inc. (at $13.49 each, total $5K) Filed: Aug 11, 2026 | ID: 055859
Read more📋 Atlas Venture Fund XI, L.P. (Shareholder) plans to sell 2K shares of Korro Bio, Inc. (at $13.49 each, total $24K) Filed: Aug 11, 2026 | ID: 055858
Read moreVincent Loic A 🟢 acquired 7.5K shares of Korro Bio, Inc. (KRRO) Transaction Date: Jul 15, 2026 | Filing ID: 306743
Read moreDolan Oliver 🟢 acquired 5.5K shares of Korro Bio, Inc. (KRRO) Transaction Date: Jul 15, 2026 | Filing ID: 306742
Read moreCerio Jeffrey 🟢 acquired 6.5K shares of Korro Bio, Inc. (KRRO) Transaction Date: Jul 15, 2026 | Filing ID: 306739
Read moreFORMELA JEAN FRANCOIS 🔴 sold 110.0K shares of Korro Bio, Inc. (KRRO) at $14.03 ($1.5M) Transaction Date: Jul 02, 2026 | Filing ID: 000006
Read more📋 Atlas Venture Fund XI, L.P. (Shareholder) plans to sell 817 shares of Korro Bio, Inc. (at $14.00 each, total $11K) Filed: Jul 06, 2026 | ID: 047352
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06677307 | A Phase 1/2a, Single- and Multiple-dose Escalation Study of KRRO-110 | Phase1 | Alpha-1 Anti-trypsin Deficiency | Terminated | 2025-01-13 | 2025-12-15 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| KRRO-110 | Other | Phase PHASE1 | Alpha-1 Anti-trypsin Deficiency | TERMINATED | NCT06677307 |
| KRRO-110 | Other | Phase PHASE1 | Alpha-1 Anti-trypsin Deficiency | TERMINATED | NCT06677307 |
| KRRO-110 | DRUG | Phase PHASE1 | Alpha-1 Anti-trypsin Deficiency | ACTIVE_NOT_RECRUITING | NCT06677307 |